Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03280121
Other study ID # D031517
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 5, 2018
Est. completion date October 26, 2020

Study information

Verified date October 2020
Source EndoGastric Solutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device


Description:

Evaluation of the relative merits, safety and effectiveness of the EsophyX ZR transoral device in performing the standardized TIF 2.0 procedure preceded by laparoscopic Hiatal Hernia repair in PPI-prescribed patients with persistent "troublesome symptoms" per the Montreal consensus definition


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date October 26, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 72 Years
Eligibility Inclusion Criteria: 1. Age 18-72 years 2. Dependent upon daily PPIs for > 6 months. Daily use is defined as a double dose, or full dose or half dose taken daily for more than 80% of the total number of days during the proceeding evaluation period 3. Troublesome symptoms, specifically heartburn or regurgitation, while on optimized dose of PPI's Troublesome heartburn or regurgitation symptoms are those which occur a minimum of 2 days a week and are mild to severe in severity 4. Abnormal ambulatory (Bravo) pH study after off PPI therapy for 7 days, i.e. > 5.3% of the time with pH < 4 in a 48-hour monitoring period 5. Normal or near normal esophageal motility (by Upper GI/ esophagram or manometry as required) 6. Pre-enrollment Hiatal Hernia (axial height and transverse dimension) from > 2 cm up to 4 cm inclusive. 7. Patient willing to cooperate with post-operative dietary recommendations and assessment tests at the requisite follow-up visits 8. Signed informed consent Exclusion Criteria 1. BMI > 35 2. Hiatal hernia = 2 and > 4 cm 3. Esophagitis Los Angeles grade C or D 4. Esophageal ulcer 5. Esophageal stricture 6. Long-segment Barretts esophagus (Prague: C > 1, M > 3) 7. Esophageal motility disorder 8. Pregnancy or plans for pregnancy in the next 12 months (in females) 9. Immunosuppression 10. ASA > 2 11. Portal hypertension and/or varices 12. History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis 13. Active gastro-duodenal ulcer disease 14. Gastric outlet obstruction or stenosis 15. Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment 16. Coagulation disorders 17. Atypical symptoms including gas bloat and dysphagia. 18. Any other presenting condition that in the opinion of the investigator would not make participation in this study in the patient's best interest. Post Enrollment Exclusion - 1. Inability to repair Hiatal hernia with at least 2cm of intra-abdominal esophagus length.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EsophyX ZR transoral device
TIF

Locations

Country Name City State
United States Elkhart General Hospital Elkhart Indiana
United States Aspirus Iron River Hospital Iron River Michigan
United States Northern Nevada Medical Center Sparks Nevada

Sponsors (1)

Lead Sponsor Collaborator
EndoGastric Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary pH Study Number of Participants with Normalization of Esophageal Acid Exposure. Normalization in esophageal acid exposure is defined by = 5.3% of total time pH < 4 in 48 hour monitoring period
Secondary Number of Participants With a Change in Troublesome Symptoms From Baseline Per Montreal Consensus definition, troublesome symptoms are mild symptoms occurring two (2) or more days per week, or moderate/severe symptoms occurring more than 1 day per week 6 months
Secondary Number of Participants With a Change in PPI Consumption From Baseline to 6 Months from daily use to occasional use or none at all. 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05068089 - Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux
Terminated NCT02708303 - Mayo Clinic Foregut Surgery Report Card Questionnaire
Completed NCT03536169 - Utilization of Anti-reflux Treatment and Course of Illness Leading to Reoperation
Completed NCT01307982 - Comparative Anti-Reflux Procedures in Neurologically Impaired Children N/A